From the Longkanker Nederland website, 1st June 2018

Through various channels, including ‘Ask the lung doctor’ and Facebook, we have received several questions about immunotherapy. 

From 1st June atezolizumab will be reimbursed from the basic package (healthcare provision within the Netherlands). So this a great moment to bring to your attention our renewed list of questions and answers about immunotherapy.

This list contains general questions about immunotherapy and questions specifically about the three immunotherapy drugs: nivolumab, pembrolizumab and atezolizumab. Read the questions and answers about immunotherapy

Booklet with 95 questions

Do you want more information about immunotherapy? Starting this week, the booklet  ’95 questions about immunotherapy for lung cancer’ can be ordered via our order page.